1. Home
  2. NUVL vs GXO Comparison

NUVL vs GXO Comparison

Compare NUVL & GXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$109.56

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo GXO Logistics Inc.

GXO

GXO Logistics Inc.

HOLD

Current Price

$52.44

Market Cap

5.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
GXO
Founded
2017
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Transportation Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
5.4B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
GXO
Price
$109.56
$52.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
12
Target Price
$134.29
$61.00
AVG Volume (30 Days)
756.3K
1.0M
Earning Date
10-30-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.76
Revenue
N/A
$12,921,000,000.00
Revenue This Year
N/A
$13.31
Revenue Next Year
N/A
$5.86
P/E Ratio
N/A
$69.03
Revenue Growth
N/A
16.94
52 Week Low
$55.54
$30.46
52 Week High
$112.88
$57.99

Technical Indicators

Market Signals
Indicator
NUVL
GXO
Relative Strength Index (RSI) 62.75 57.11
Support Level $103.51 $50.06
Resistance Level $112.11 $52.95
Average True Range (ATR) 5.16 1.38
MACD -0.24 0.57
Stochastic Oscillator 83.81 94.59

Price Performance

Historical Comparison
NUVL
GXO

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About GXO GXO Logistics Inc.

GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.

Share on Social Networks: